Isotope enrichment startup Hexium has launched from stealth with $12m funding to advance atomic vapour laser isotope separation (AVLIS) technology.
The company aims to re-establish US leadership in isotope enrichment, focusing initially on lithium-6 and lithium-7 for nuclear fuel cycles.
Go deeper with GlobalData
The funding includes an $8m seed round co-led by MaC Venture Capital and Refactor, with contributions from R7 Partners, Overture VC, Humba Ventures, Julian Capital and others.
An additional $4m was also raised through primarily non-dilutive private financing.
Hexium is modernising AVLIS technology, originally developed by the Lawrence Livermore National Laboratory (LLNL).
Hexium’s initiative aims to demonstrate that AVLIS is a viable method for large-scale production of enriched lithium, essential for the advanced nuclear sector’s ambitious goals.
The company is leveraging AVLIS technology, initially backed by a $2bn US Department of Energy investment, to address isotope production bottlenecks.
By focusing on lithium-6 and lithium-7, Hexium intends to reduce US reliance on foreign isotope sources, ensuring a stable domestic supply for energy, space and medical applications.
Hexium co-founder and CEO Charlie Jarrott stated: “We’ve built our demonstration facility and have a clear roadmap towards proving the most straightforward and efficient pathway to produce enriched lithium at scale.
“There is a global race to mass produce isotopes, which are critical to the future of clean energy, and this funding positions Hexium as a leader in the race to accelerate enriched lithium supply in the United States.”
Hexium’s patent-pending approach seeks to enhance US isotope production while maintaining competitive costs for clean nuclear energy.
AVLIS technology is known for its ability to extract high-purity isotopes quickly and affordably, with a compact facility footprint and established supply chain.
MaC Venture Capital general partner Mike Palank stated: “[Hexium is] making impressive progress on critical isotope supply chain challenges facing several key industries, including nuclear fusion, fission and medicine.
“This team’s clear path to commercialisation and obsession with execution should be an example for all hard tech founders seeking to change the world.”
AVLIS can also be adapted for other critical isotopes, bolstering the US position in the global market.
Founded in October 2023, Hexium has made swift progress since it emerged from stealth.
The company has invested in laboratory and machine construction, with lithium separation demonstrations expected.
Hexium also collaborates with LLNL and engages with early customers in the fusion, fission and medical industries, further advancing its strategic goals.
